<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04859816</url>
  </required_header>
  <id_info>
    <org_study_id>FAT-BAR</org_study_id>
    <nct_id>NCT04859816</nct_id>
  </id_info>
  <brief_title>Fat Absorption and Metabolism After Roux-en-Y Gastric Bypass</brief_title>
  <acronym>FAT-BAR</acronym>
  <official_title>Fat Absorption and Metabolism After Roux-en-Y Gastric Bypass</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hvidovre University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Using intravenous and oral administration of stable isotope tracers, we will investigate the&#xD;
      importance of altered fat absorption and altered whole body fat metabolism for the reduced&#xD;
      postprandial systemic TAG concentrations in non-diabetic patients in weight stable phase&#xD;
      after RYGB.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve of plasma triacylglycerol</measure>
    <time_frame>6 hours</time_frame>
    <description>During a high-fat liquid mixed meal test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recovery of oral stable triacylglycerol isotope tracer in feces</measure>
    <time_frame>4 days</time_frame>
    <description>An oral stable triacylglycerol isotope tracer will be administered during a high-fat liquid mixed meal test. Feces will be collected the following 4 days to determine the recovery of the tracer in feces.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Bariatric Surgery</condition>
  <arm_group>
    <arm_group_label>Roux-en-Y gastric bypass operated participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Roux-en-Y gastric bypass operated participants in weight stable phase &gt; 1 year from surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Age, sex, and BMI-matched un-operated participants.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Metabolic test</intervention_name>
    <description>Iv and oral administration of stable isotope tracers during fasting and a high-fat liquid mixed meal</description>
    <arm_group_label>Control participants</arm_group_label>
    <arm_group_label>Roux-en-Y gastric bypass operated participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>DXA-scan</intervention_name>
    <description>Dual energy X-ray Absorptiometry scan of whole-body fat</description>
    <arm_group_label>Control participants</arm_group_label>
    <arm_group_label>Roux-en-Y gastric bypass operated participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MRS</intervention_name>
    <description>Magnetic resonance spectroscopy of liver fat content</description>
    <arm_group_label>Control participants</arm_group_label>
    <arm_group_label>Roux-en-Y gastric bypass operated participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Feces collection</intervention_name>
    <description>4-day feces collection</description>
    <arm_group_label>Control participants</arm_group_label>
    <arm_group_label>Roux-en-Y gastric bypass operated participants</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria, RYGB&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  RYGB &gt; 12 months prior to inclusion&#xD;
&#xD;
          -  Weight stable (± 3 kg during the last month)&#xD;
&#xD;
          -  HbA1c &lt; 48 mmol/mol before surgery, and no history of diabetes&#xD;
&#xD;
          -  HbA1c &lt; 48 mmol/mol and fasting plasma glucose &lt; 6.1 mmol/l at inclusion&#xD;
&#xD;
        Inclusion criteria, CON&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  No former bariatric surgery&#xD;
&#xD;
          -  Weight stable (± 3 kg during the last month)&#xD;
&#xD;
          -  HbA1c &lt; 48 mmol/mol, fasting plasma glucose &lt; 6.1, and no history of diabetes&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  Thyrotoxicosis or inadequately treated hypothyreosis&#xD;
&#xD;
          -  Haemoglobin &lt; 6.5 mmol/l at inclusion&#xD;
&#xD;
          -  Pregnancy (pregnancy test in fertile woman before enrolment) or breast feeding&#xD;
&#xD;
          -  Medication affecting the planned examinations which cannot be paused during the study&#xD;
             period.&#xD;
&#xD;
          -  Adherence to extreme diets with excessively high or low contributions from certain&#xD;
             macronutrients (e.g. ketogenic diet)&#xD;
&#xD;
          -  Complications restricting eating behavior (e.g. postprandial hypoglycemia, vomiting or&#xD;
             strictures)&#xD;
&#xD;
          -  MR contraindications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Morten G Hindsø, MD</last_name>
    <phone>38626371</phone>
    <email>morten.hindsoe@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kirstine N Bojsen-Møller, MD</last_name>
    <phone>38626371</phone>
    <email>kirstine.nyvold.bojsen-moeller@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hvidovre Hospital</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Morten G Hindsø, MD</last_name>
      <phone>38626371</phone>
      <email>morten.hindsoe@regionh.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 12, 2021</study_first_submitted>
  <study_first_submitted_qc>April 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2021</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hvidovre University Hospital</investigator_affiliation>
    <investigator_full_name>Morten Gadegaard Hindsø, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>fat</keyword>
  <keyword>triglyceride</keyword>
  <keyword>triacylglycerol</keyword>
  <keyword>Roux-en-Y gastric bypass</keyword>
  <keyword>malabsorption</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

